A Pre-Approval Information Exchange (PIE) Webinar sponsored by Sydnexis.

The speakers will discuss the rise in prevalence, severity, and irreversible vision threatening co-morbidities associated with myopia. We will explore the latest published data and discuss the primary causes of myopia, both genetic and environmental. We will also examine the significant health impact this epidemic has on patients and caregivers throughout their lives. Finally, the presentation will highlight an investigational Rx treatment for slowing myopic progression in pediatric patients. SYD-101 has an assigned PDUFA date of October 23, 2025.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.
This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Pre-Approval Information Exchange (PIE) Webinar sponsored by Apellis Pharmaceuticals, Inc.

C3G and Primary IC-MPGN are 2 rare, chronic glomerular diseases that are driven by complement system overactivation and lead to severe kidney damage. Review of the results of the VALIANT Phase 3 trial, evaluating pegcetacoplan as an investigational product for use in C3G and IC-MPGN. The safety and efficacy of pegcetacoplan in C3G and IC-MPGN have not been established.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

Join us for a webinar on ER+/HER2- Metastatic Breast Cancer, a disease affecting nearly 150,000 people in the U.S. Despite advancements in treatment, significant gaps remain in access, affordability, and comprehensive care. This session will feature a clinical key opinion leader and payer participants from the roundtable convened by AMCP in February 2025. Presenters will characterize the clinical and QOL burden of ER+/HER2, explore the mechanisms of action of current therapies, review current treatment options, describe therapeutics that targets ERs, and outline payer strategies to facilitate precision oncology care.

AMCP eLearning Day is an educational experience focused on the hottest topics related to aging. This is an opportunity to learn live from expert faculty while earning CPE from home. The live event consists of two 1-hour virtual sessions held on May 14. These sessions will be recorded and converted to enduring activities on AMCP Learn by May 21. 

A Pre-Approval Information Exchange (PIE) Webinar sponsored by Ionis Pharmaceuticals, Inc.

This presentation includes information about a novel and investigational RNA-targeted long-term prophylactic
treatment option for hereditary angioedema (HAE) and provides the following:
    • Overview of HAE, including the clinical and economic burdens experienced by patients and
healthcare systems
    • Review of efficacy and safety data from the pivotal and open-label extension clinical trials

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.
 

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Science & Innovation Webinar, presented by Mesoblast.

Join us for an insightful webinar on the advancements in treating pediatric steroid-refractory acute versus host disease (SR-aGVHD) with RYONCIL®, which was approved by the FDA on December 19, 2024. We will delve into the significant unmet need in SR-aGVHD, a condition with high morbidity and mortality rates, and how Ryoncil’s safety and efficacy offers a promising new therapeutic option that has significant impact on long-term survival outcomes. We will also explore the potential to deliver significant healthcare cost savings due to substantial long-term survival benefits, utilizing health economic models for ultra-rare diseases and high-impact therapies.